Y-mAbs Therapeutics Q2 2024 GAAP EPS $(0.21) Misses $(0.15) Estimate, Sales $22.798M Miss $23.019M Estimate
Portfolio Pulse from Benzinga Newsdesk
Y-mAbs Therapeutics reported a Q2 2024 GAAP EPS of $(0.21), missing the estimate of $(0.15). Sales were $22.798M, also missing the estimate of $23.019M.
August 12, 2024 | 10:31 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Y-mAbs Therapeutics reported a Q2 2024 GAAP EPS of $(0.21), missing the estimate of $(0.15). Sales were $22.798M, also missing the estimate of $23.019M.
The company's earnings and sales both missed estimates, which is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100